{
  "image_filename": "figure_p1_det_0_017.png",
  "image_path": "Hsiao_et_al.__2023_/extracted/figures/figure_p1_det_0_017.png",
  "image_type": "Figure",
  "page_number": 1,
  "block_id": "det_0_017",
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "supports_claim": false,
  "explanation": "The image is the title header of an original research article showing the article title 'Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age' and a list of authors; no data, figures, or results are visible. The image contains only the article title and author names and provides no study data or statements about immune response breadth or cross-protection, so it does not support the claim. Note: Analysis limited by the image showing only the title page without any results or discussion text.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "The image is the title header of an original research article showing the article title 'Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age' and a list of authors; no data, figures, or results are visible.",
    "evidence_found": null,
    "reasoning": "The image contains only the article title and author names and provides no study data or statements about immune response breadth or cross-protection, so it does not support the claim.",
    "confidence_notes": "Analysis limited by the image showing only the title page without any results or discussion text."
  }
}